AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20803300 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) administered twice daily, titrated from 250 to 2,000 mg/day
Number of subjects: 32
Study 20803300 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily
Number of subjects: 32
Study 17937961 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tolterodine extended release
Number of subjects: 30
Study 17937961 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg tolterodine extended release
Number of subjects: 30
Study 17937961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16110271 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 30
Study 16110271 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 12375315 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) coadministered with Hydroxychloroquine (HCQ)
Number of subjects: 10
Study 12375315 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 10
Study 12375315 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) alone
Number of subjects: 10
Study 10442197 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomeric infusor (Baxter)
Number of subjects: 10
Study 10442197 — intervention group
Group type: COMPARATOR
Intervention: Mechanical, electronically controlled pump (CADD‐1, Pharmacia)
Number of subjects: 10
Study 7800329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg), administered at admission and repeated 6 hours later if labor was not established
Number of subjects: 100
Study 7800329 — intervention group
Group type: COMPARATOR
Intervention: Conservative management for 24 hours
Number of subjects: 100
Study 7800329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg)
Number of subjects: 100
Study 7800329 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 100
Study 2181769 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide administered post-TURP
Number of subjects: 14
Study 2181769 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 14
Study 383033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 16
Study 383033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with methyldopa
Number of subjects: 16
Study 383033 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 16
Study 30587533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin (5 days of intranasal plus topical application to the intranasal, periumbilical, and perianal areas)
Number of subjects: 155
Study 30587533 — intervention group
Group type: COMPARATOR
Intervention: Control (no mupirocin)
Number of subjects: 155
Study 30587533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin (5 days of intranasal plus topical application)
Number of subjects: 155
Study 28939642 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat Western diet
Number of subjects: 42
Study 28939642 — intervention group
Group type: COMPARATOR
Intervention: Low-fat traditional Hispanic diet
Number of subjects: 42
Study 28939642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat quality in BPRHS subset
Number of subjects: 42
Study 26595029 — intervention group
Group type: COMPARATOR
Intervention: Classic vertical plication (group A)
Number of subjects: 98
Study 26595029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical plication with customized horizontal plications (group B)
Number of subjects: 98
Study 26595029 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 98
Study 23571650 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact® (IMN)
Number of subjects: 8
Study 23571650 — intervention group
Group type: COMPARATOR
Intervention: Isosource® (STD)
Number of subjects: 8
Study 21771255 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS (high frequency, low intensity)
Number of subjects: 121
Study 21771255 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS (AL-TENS, low frequency, high intensity)
Number of subjects: 121
Study 21771255 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (no current)
Number of subjects: 121
Study 19454869 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 350
Study 19454869 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 350
Study 19454869 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (overall phase)
Number of subjects: 350
Study 16777518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ECGs
Number of subjects: 13
Study 16777518 — intervention group
Group type: COMPARATOR
Intervention: Standard ECGs
Number of subjects: 13
Study 12532318 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (7.5-30 mg)
Number of subjects: 60
Study 12532318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12532318 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam plus CBT
Number of subjects: 60
Study 10364861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellcor N-3000 pulse oximeter
Number of subjects: 22
Study 10364861 — intervention group
Group type: COMPARATOR
Intervention: Nellcor N-200 pulse oximeter
Number of subjects: 22
Study 8652325 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 6 mg
Number of subjects: 150
Study 8652325 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 1 mg
Number of subjects: 150
Study 8652325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2049961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg orally once daily for 3 weeks)
Number of subjects: 52
Study 2049961 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (320/1,600 mg orally once daily for 3 weeks)
Number of subjects: 52
Study 6388218 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (100 mg, 2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Number of subjects: 30
Study 6388218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Number of subjects: 30
Study 6388218 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 30
Study 6388218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30991984 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision-assisted flapless corticotomy
Number of subjects: 34
Study 30991984 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthodontic treatment
Number of subjects: 34
Study 29923427 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg/day)
Number of subjects: 20
Study 29923427 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 26851146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum osmolality (≤284 mOsm/kg)
Number of subjects: 3744
Study 26851146 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mOsm/kg decrease in osmolality
Number of subjects: 3744
Study 26851146 — intervention group
Group type: COMPARATOR
Intervention: Normal serum osmolality (285 to 300 mOsm/kg)
Number of subjects: 3744
Study 26851146 — intervention group
Group type: COMPARATOR
Intervention: High serum osmolality (≥300 mOsm/kg)
Number of subjects: 3744
Study 25434622 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® cream (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) applied for 60 minutes prior to cryotherapy
Number of subjects: 64
Study 25434622 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied for 60 minutes prior to cryotherapy
Number of subjects: 64
Study 25434622 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® cream (for those with more than 1 wart)
Number of subjects: 64
Study 25434622 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® cream (for those with only 1 wart)
Number of subjects: 64
Study 23167380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-Emotive Behavior Therapy (REBT) for 45 days (ten sessions)
Number of subjects: 88
Study 23167380 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 21126954 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/r100
Number of subjects: 0
Study 21126954 — intervention group
Group type: COMPARATOR
Intervention: FPV/r200
Number of subjects: 0
Study 17141936 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression force during CPR
Number of subjects: 91
Study 17141936 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression depth during CPR
Number of subjects: 91
Study 17141936 — intervention group
Group type: EXPERIMENTAL
Intervention: Force needed to reach 38 mm compression depth (F38)
Number of subjects: 91
Study 17141936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean compression force
Number of subjects: 91
Study 17141936 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest stiffness
Number of subjects: 91
Study 17141936 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual force during decompression
Number of subjects: 91
Study 15851952 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lyophilisate application of sodium fluorescein (204 microg)
Number of subjects: 22
Study 15851952 — intervention group
Group type: COMPARATOR
Intervention: Three conventional eye drops of sodium fluorescein (40 microl each, 68 microg total)
Number of subjects: 22
Study 11988381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print plus tailored telephone counseling (TP+TC)
Number of subjects: 0
Study 11988381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print (TP)
Number of subjects: 0
Study 11988381 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 9934749 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Number of subjects: 84
Study 9934749 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Number of subjects: 84
Study 9934749 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 million units (MU) of lymphoblastoid interferon alpha (IFN)
Number of subjects: 84
Study 9934749 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 million units (MU) of lymphoblastoid interferon alpha (IFN)
Number of subjects: 84
Study 7594330 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg (n = 9)
Number of subjects: 86
Study 7594330 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole (LPZ) 30 mg (n = 16)
Number of subjects: 86
Study 7594330 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus plaunotol 480 mg (n = 13)
Number of subjects: 86
Study 7594330 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus ecabet sodium 2 g (n = 11)
Number of subjects: 86
Study 7594330 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus clarithromycin 600 mg (the first 2 weeks; n = 11)
Number of subjects: 86
Study 7594330 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus plaunotol 480 mg plus clarithromycin 600 mg (the first 2 weeks; n = 13)
Number of subjects: 86
Study 7594330 — intervention group
Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus ecabet sodium 2 g plus amoxicillin 1,500 mg (the first 2 weeks; n = 13)
Number of subjects: 86
Study 2924606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 14
Study 2924606 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 14
Study 2924606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 83808 — intervention group
Group type: EXPERIMENTAL
Intervention: Kystosol
Number of subjects: 27
Study 83808 — intervention group
Group type: COMPARATOR
Intervention: Glycine
Number of subjects: 27
Study 31330023 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Proffen app-based intervention
Number of subjects: 25
Study 31570733 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate (AM)
Number of subjects: 68
Study 31570733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 28503982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc replacement
Number of subjects: 151
Study 28503982 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 151
Study 28503982 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-neurogenic pain drawings (Ransford method)
Number of subjects: 151
Study 28503982 — intervention group
Group type: EXPERIMENTAL
Intervention: Markings in the head region
Number of subjects: 151
Study 28503982 — intervention group
Group type: EXPERIMENTAL
Intervention: Markings in the neck and lower arm region
Number of subjects: 151
Study 26627989 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA closure
Number of subjects: 1114
Study 26627989 — intervention group
Group type: COMPARATOR
Intervention: Long-term warfarin therapy
Number of subjects: 1114
Study 26627989 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of major bleeding rates
Number of subjects: 1114
Study 23645099 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol administration (0.25 μg bid for 1 week)
Number of subjects: 38
Study 23645099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU single oral dose)
Number of subjects: 38
Study 23645099 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 38
Study 20236252 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° laser trabeculoplasty and topical betaxolol eye drops B.I.D.
Number of subjects: 128
Study 19026450 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mother-Infant Transaction Program (7 sessions prior to discharge and 2 sessions over 3 months)
Number of subjects: 0
Study 19026450 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 17257991 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion of washed shed blood or discarding of unwashed blood
Number of subjects: 37
Study 17257991 — intervention group
Group type: COMPARATOR
Intervention: Retransfusion of unwashed shed blood
Number of subjects: 37
Study 15514407 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 138
Study 15514407 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 138
Study 15514407 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine with lithium addition
Number of subjects: 138
Study 15514407 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine with lithium addition
Number of subjects: 138
Study 11527892 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration on the day of oocyte retrieval
Number of subjects: 87
Study 11527892 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (placebo control)
Number of subjects: 87
Study 11527892 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 87
Study 9085712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol in light alcohol consumers
Number of subjects: 10
Study 9085712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol in light alcohol consumers
Number of subjects: 10
Study 9085712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol in moderate alcohol consumers
Number of subjects: 10
Study 9085712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol in moderate alcohol consumers
Number of subjects: 10
Study 9085712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg and 1.0 g/kg alcohol in light consumers (frequency and duration measures)
Number of subjects: 10
Study 9085712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol in moderate consumers (duration measure)
Number of subjects: 10
Study 7942724 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of quadruple therapy
Number of subjects: 111
Study 7942724 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of quadruple therapy
Number of subjects: 111
Study 2598985 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-924 (CI) 600 mg/day
Number of subjects: 35
Study 2598985 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-924 (CI)
Number of subjects: 35
Study 788733 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic isoquinoline compound (U.K. 2371)
Number of subjects: 262
Study 788733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 30903442 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Affirmation
Number of subjects: 603
Study 30903442 — intervention group
Group type: COMPARATOR
Intervention: No Self-Affirmation Control
Number of subjects: 603
Study 27225535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 200
Study 27225535 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 200
Study 26653189 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 597
Study 26653189 — intervention group
Group type: COMPARATOR
Intervention: Usual chronic obstructive pulmonary disease (control group)
Number of subjects: 597
Study 26653189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-related desaturation
Number of subjects: 597
Study 23131613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives (HC women)
Number of subjects: 78
Study 23131613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Stress (CPS)
Number of subjects: 78
Study 23131613 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 78
Study 21618499 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative duplex imaging (group 1)
Number of subjects: 293
Study 21618499 — intervention group
Group type: COMPARATOR
Intervention: No preoperative duplex imaging (group 2)
Number of subjects: 293
Study 21618499 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) measured with the Short Form 36 questionnaire
Number of subjects: 293
Study 19099308 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) program and exercises
Number of subjects: 41
Study 19099308 — intervention group
Group type: COMPARATOR
Intervention: Exercises (Control group)
Number of subjects: 41
Study 22765645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose levofloxacin 750 mg intravenously once daily, followed by the same dose orally at discharge when clinically improved.
Number of subjects: 40
Study 22765645 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2.0 g intravenously once daily plus oral azithromycin 500 mg for 3 consecutive days, followed by oral cefpodoxime 200 mg per day at discharge after clinical improvement.
Number of subjects: 40
Study 22765645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose levofloxacin
Number of subjects: 40
Study 22765645 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus azithromycin
Number of subjects: 40
Study 15796351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestrectomy
Number of subjects: 84
Study 15796351 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 84
Study 12036814 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 33
Study 9857493 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit measure of strategy discovery
Number of subjects: 0
Study 9857493 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit measure of strategy discovery
Number of subjects: 0
Study 7740334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined doxorubicin (50 mg/m2 day 1) and vinorelbine (25 mg/m2 days 1 and 8) every 21 days
Number of subjects: 62
Study 2258080 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2 IV every 28 days)
Number of subjects: 41
Study 2258080 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 41
Study 369643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent compression dressings
Number of subjects: 0
Study 369643 — intervention group
Group type: COMPARATOR
Intervention: Standard method of care
Number of subjects: 0
Study 11326179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 3 mg (group 1)
Number of subjects: 68
Study 11326179 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 68
Study 11326179 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 68
Study 11326179 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 68
Study 30678863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonists (MRA)
Number of subjects: 0
Study 29995743 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal antisepsis policies
Number of subjects: 2013
Study 29995743 — intervention group
Group type: COMPARATOR
Intervention: No vaginal antisepsis policies
Number of subjects: 2013
Study 27043452 — intervention group
Group type: EXPERIMENTAL
Intervention: MP‐AzeFlu (Dymista(®), 1 spray/nostril bid)
Number of subjects: 353
Study 27043452 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP, 1 spray/nostril bid)
Number of subjects: 353
Study 24281730 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine + Montelukast
Number of subjects: 40
Study 24281730 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine + Montelukast
Number of subjects: 40
Study 24281730 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (monotherapy)
Number of subjects: 40
Study 24281730 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine (monotherapy)
Number of subjects: 40
Study 23200287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment for adolescents (MBT-A)
Number of subjects: 80
Study 23200287 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study 20070811 — intervention group
Group type: EXPERIMENTAL
Intervention: Research papers published in the journal
Number of subjects: 168